Click to view your profile
Click to search for condition or expert
Click to open main menu
Hodgkin Lymphoma Latest Advances
Find the Latest Research About Hodgkin Lymphoma
Save
Bookmark
Share
Share
Overview
Find a Doctor
Latest Advances
Clinical Trials
Treatments
Customize your search results with filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 02/19/2023
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 202 publications
See more filters
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Condition:
High-Risk Classic Hodgkin Lymphoma
Journal:
The Lancet. Haematology
Treatment Used:
Brentuximab Vedotin Plus Nivolumab
Number of Patients:
59
Published:
November 20, 2022
VIEW PUBLICATION
Survival and prognosis analysis of patients with Hodgkin lymphoma treated with standard treatment paradigm.
Condition:
Hodgkin Lymphoma (HL)
Journal:
Zhonghua yi xue za zhi
Treatment Used:
Standard First-Line Therapy
Number of Patients:
746
Published:
November 01, 2022
VIEW PUBLICATION
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Condition:
Hodgkin Lymphoma (HL)
Journal:
American journal of hematology
Treatment Used:
Chemotherapy, Stem Cell Transplantation, Radiation Therapy, and Targeted Therapies
Number of Patients:
0
Published:
October 10, 2022
VIEW PUBLICATION
Treatment strategy for pediatric Hodgkin lymphoma.
Condition:
Pediatric Hodgkin Lymphoma (HL)
Journal:
[Rinsho ketsueki] The Japanese journal of clinical hematology
Treatment Used:
Combination of Multiagent Chemotherapy and Low-Dose Radiation Therapy and Targeted Therapy
Number of Patients:
0
Published:
October 05, 2022
VIEW PUBLICATION
HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1.
Condition:
Stage III/IV Classical Hodgkin Lymphoma (cHL)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Brentuximab Vedotin Plus Chemotherapy
Published:
September 27, 2022
VIEW PUBLICATION
HL-300 Efficacy of Brentuximab Vedotin Plus Conventional Chemotherapy Regimens as Pre-Autologous Stem Cell Transplantation Re-Induction Salvage Therapy in Relapsed/Refractory Classical Hodgkin Lymphoma.
Condition:
Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Brentuximab Vedotin (BV) Plus Conventional Chemotherapy Regimens
Number of Patients:
20
Published:
September 27, 2022
VIEW PUBLICATION
HL-367 ASCT for Treatment-Resistant Mediastinal Gray Zone Lymphoma.
Condition:
Treatment-Resistant Mediastinal Gray Zone Lymphoma (GZL)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
HL-367 ASCT
Published:
September 27, 2022
VIEW PUBLICATION
CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma.
Condition:
Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
Journal:
Investigational new drugs
Treatment Used:
Camidanlumab Tesirine
Number of Patients:
0
Published:
September 08, 2022
VIEW PUBLICATION
Visceral leishmaniasis caused by Leishmania (Leishmania) amazonensis associated with Hodgkin's lymphoma.
Condition:
Visceral Leishmaniasis (VL) in Patient with Hodgkin's Lymphoma
Journal:
Revista do Instituto de Medicina Tropical de Sao Paulo
Treatment Used:
Liposomal Amphotericin B and Chemotherapy
Number of Patients:
1
Published:
September 08, 2022
VIEW PUBLICATION
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Condition:
Refractory/Relapsed (R/R) Hodgkin Lymphoma
Journal:
Leukemia & lymphoma
Treatment Used:
Brentuximab Vedotin (BV) Combined with Ifosfamide-Carboplatin-Etoposide (ICE)
Number of Patients:
52
Published:
August 17, 2022
VIEW PUBLICATION
Relapsed Hodgkin lymphoma with only breast involvement: a rare case report.
Condition:
Relapsed Hodgkin Lymphoma
Journal:
The Pan African medical journal
Treatment Used:
Chemotheray
Number of Patients:
1
Published:
August 01, 2022
VIEW PUBLICATION
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.
Condition:
Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Journal:
Leukemia & lymphoma
Treatment Used:
AFM13
Number of Patients:
25
Published:
July 18, 2022
VIEW PUBLICATION
Showing 1-12 of 202
Next
Last Updated: 02/19/2023